. . . for New Presumptive Field Narcotics Testing Products with Fieldtests LLC

QuantRx Biomedical Corporation, (OTCBB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has concluded the development of the Fieldtests ID product line for identifying drugs-of-abuse residue. QuantRx has entered into an exclusive manufacturing agreement with Fieldtests LLC. These new products represent a break-through technology for the field-testing of narcotic residues in both the law enforcement and occupational health marketplace.

. . . for Development of Diagnosis and Treatment Agents for Alzheimer's Disease (AD)

QuantRx Biomedical Corporation, (OTCBB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that its molecular imaging group, FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, has entered into a license agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and treatment of Alzheimer’s disease (AD). The licensed technologies, which were co-developed by FluoroPharma and MGH scientists, target multiple biological processes associated with Alzheimer’s disease.

. . . A Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)

QuantRx Biomedical Corporation, (OTCBB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, is commencing Phase I clinical trials for BFPET following institutional review board (IRB) approval of the proposed studies. The Phase I trial is a single center, open label study, designed to evaluate safety, distribution, and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging in healthy subjects. The study will be led by Dr. Alan Fischman, Professor of Radiology at Harvard Medical School and former Director of the Nuclear Medicine Division at Massachusetts General Hospital. BFPET is FluoroPharma’s second cardiovascular PET agent to enter clinical trials.

Company Receives Patent in Canada for PAD-Based Diagnostic Collection System

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that the Canadian Intellectual Property Office (CIPO) has approved its PADKit® patent application. This patent enhances the international protection for QuantRx's proprietary Miniform based diagnostic sample collection systems, trademarked PADKit®, for laboratory sample collection, and PADChek(TM), for consumer testing.

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has entered into a Memorandum of Understanding agreement with Jant Pharmacal to form a strategic alliance to develop and commercialize new technologies and products in the areas of diagnostics and monitoring.

QuantRx and Jant are exploring quantative Point of Care technologies in areas of oncology, cardiovascular, and other emerging markets. The technologies are supported by strong IP positions as well as proof of concept and clinical data. QuantRx and Jant plan to launch several new products in 2008.

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, presented positive Phase I safety results for CardioPET, its lead product. The trial was designed to evaluate safety, distribution and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects and patients with Coronary Artery Disease (CAD). Dr. David Elmaleh, Chairman and scientific founder of FluoroPharma, presented findings from the Phase I trial at the "Clinical Trials Update" session at a Society of Nuclear Medicine conference in Denver, Colorado.

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that Dr. David Elmaleh, Chairman and Chief Scientific Founder of FluoroPharma, will present findings from the company's Phase I trial for CardioPET, a metabolic cardiac imaging agent for the assessment of coronary artery disease at the Society of Nuclear Medicine's (SNM) annual High Country Nuclear Medicine Conference in Denver, Colorado. During his presentation, Dr. Elmaleh will discuss the results of the recently completed trial, including findings in healthy subjects and patients with CAD. The presentation will be part of the "Clinical Trials Update" session on Saturday, March 1, 2008.

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has entered into a second development and manufacturing agreement with ALT BioScience, LLC to continue the development of their professional periodontal screening product, the second oral healthcare product in their portfolio. The products will be available for distribution in the dental and consumer marketplaces with applications including halitosis, gingivitis, and periodontal disease.

The first QuantRx-developed product is a consumer quick-check test for detection of halitosis and gingivitis and is also based on ALT BioScience's oral health platform technology. Product introduction into the professional market is anticipated in early 2009.

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that it has launched the QuantRx Affirm Drugs-of-Abuse Test product line in both the U.S. and European markets. This product line, along with its RapidSense line, enables QuantRx to offer its customer base a complete spectrum of drugs-of-abuse test product lines.

New One-Step Lateral Flow Device to Quickly and Efficiently Measure Hormone Levels for Women Attempting to Conceive

QuantRx Biomedical Corporation (OTC BB:QTXB.OB - News), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance on its Follicle Stimulating Hormone (FSH) lateral flow immunoassay test for the detection of FSH at 10ng/ml. The QuantRx Biomedical Female Fertility test is a one-step lateral flow device that determines ovarian reserve indirectly by measuring FSH in first morning urine. The product is intended to aid women who are attempting to conceive and are experiencing difficulty. The QuantRx Biomedical Female Fertility test can produce results within 15 minutes, approximately half the time of the sole competing product currently in the marketplace.

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), an emerging leader in the research and development of medical diagnostic platforms and products, is pleased to announce it has entered into a long-term agreement with Kang Na Hsiung (KNH) of Taiwan, covering the process development, manufacturing, and packaging of its PAD-based product line.

KNH is a respected manufacturing firm currently producing products under FDA cGMP controls whose client list includes Procter & Gamble and a number of other major consumer product companies. KNH has been dedicated to improving the quality of life and to protecting the environment since they were founded in 1969. Committed to quality products, superior service, and consistent innovation, KNH is making advances in the fields of personal care, hygiene, skin care, and industrial specialty products.

QuantRx® Biomedical Corporation (OTC BB:QTXB.OB - News), an emerging leader in the research and development of medical diagnostic platforms and products, today announced that FluoroPharma, its majority owned affiliate, and a company developing breakthrough cardiovascular PET molecular imaging diagnostics, has made several recent additions to its management and scientific leadership team, including Dr. Todd R. Nelson as an Independent Director and Dr. Elazer Edelman as a Scientific Advisory Board member.

Zangani Investor Community interviewed Walter Witoshkin, Chairman, CEO and President of QuantRx Biomedical Corporation. Walter discusses the impressive product portfolio of QuantRx including Unique and FluoroPharma, a QuantRx affiliate.

QuantRx Biomedical Corporation is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by either medical professionals or consumers, QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care.

QuantRx® Biomedical Corporation, an emerging leader in the research and development of medical diagnostic platforms and products, today announced that FluoroPharma, a QuantRx affiliate, completed 12 healthy volunteers in a Phase I clinical trial for CardioPET. The Phase I trial is a single center, open label study, designed to evaluate safety, distribution, and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects. The study was led by Dr. Alan Fischman, Director of the Nuclear Medicine Division at Massachusetts General Hospital. CardioPET™ was exceedingly well tolerated, with no adverse events or clinically significant laboratory findings observed. Total radiation exposure was minimal and well within safety limits. Based on these results, IRB approved the initiation of CardioPET™ in a small group of stable CAD patients.

QuantRx® Biomedical Corporation, an emerging leader in the research and development of medical diagnostic platforms and products, today announced that it has entered into an agreement with ALT BioScience, LLC to develop a portfolio of healthcare products related to oral health for distribution in the consumer and medical marketplaces.

The first QuantRx-developed product is a consumer quick-check test for detection of bad breath, to be marketed by ALT BioScience, and is based on ALT BioScience's oral health platform technology. Product introduction into the market is anticipated in late 2007.